Every 10-Q that DENTSPLY SIRONA Inc. (XRAY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XRAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XRAY filings page.
Dentsply Sirona (XRAY) reported Q3 2025 results with net sales of $904 million versus $951 million a year ago and an operating loss of $218 million. The quarter included $262 million of goodwill and intangible asset impairments, leading to a net loss of $427 million, or $2.14 per share.
Sales declined in the United States to $291 million from $374 million, while Europe rose to $382 million from $347 million. Segment mix showed Essential Dental Solutions at $357 million and Orthodontic and Implant Solutions at $205 million; Wellspect Healthcare increased to $83 million from $72 million.
Year to date, net sales were $2.719 billion versus $2.888 billion, with $497 million of impairments and a net loss of $452 million. Cash from operating activities was $134 million year to date, ending cash was $363 million. Long‑term debt was $2,017 million and current debt was $378 million. Goodwill decreased to $1,270 million from $1,597 million, and total equity was $1,478 million.